Larvol Delta - Amytrx-Therapeutics-Announces-Open-Enrollment-for-Phase-2b-Clinical-Trial-of-AMTX100-CF3-a-Promising-AntiInflammatory-Peptide-Therapeutic-for-Atopic-Dermatitis

AMTX-100 CF3 - Amytrx Therap

https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

Jun 28, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next